K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 53.65 HKD -0.56% Market Closed
Market Cap: 16B HKD

Net Margin
KeyMed Biosciences Inc

-29.5%
Current
-239%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-29.5%
=
Net Income
-257.3m
/
Revenue
872.2m

Net Margin Across Competitors

No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
16B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

Intrinsic Value
66.06 HKD
Undervaluation 19%
Intrinsic Value
Price
K
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-29.5%
=
Net Income
-257.3m
/
Revenue
872.2m
What is the Net Margin of KeyMed Biosciences Inc?

Based on KeyMed Biosciences Inc's most recent financial statements, the company has Net Margin of -29.5%.

Back to Top